New arylsulfonylhydrazones of substituted benzaldehydes as anticancer agents.
Nineteen new arylsulfonylhydrazones of substituted benzaldehydes have been prepared. The antineoplastic activity of these compounds has been assessed against murine lymphocytic leukemia P-388 and Ehrlich ascites carcinoma (EAC). The compounds investigated have not reached the criteria of good antitumor activity. However, marginal activity in P-388 system has been exhibited by one of the tested derivatives, while two others have demonstrated mild anticancer activity against EAC.